Star Therapeutics
- Health & Biotech
- South San Francisco, US
- Private
- star-therapeutics.com
South San Francisco biotech building best-in-disease therapies; led by Sanofi Ventures and Viking in a 2025 Series D, then a $200M private financing in 2026.
$325MEquity raised in 2025–20262025 $125M · 2026 $200M · 2 equity rounds
$325MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 2 rounds · 4 sources · newest first
Earlier rounds not yet sourced. Star Therapeutics raised before Sep 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Private financingAmount$200MPost-money—✓ Confirmed
- Series D financingAmount$125MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 15
- Janus Henderson Investors2
- OrbiMed1
- Sanofi1
- Viking Global Investors1
- Agent Capital
- Catalio Capital Management
- Cormorant Asset Management
- Frazier Life Sciences
- GordonMD Global Investments
- New Leaf Venture Partners
- NYBC Ventures
- RA Capital Management
- Redmile
- Sofinnova Investments
- Soleus Capital
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Parabilis MedicinesHealth · $975M in 2025–2026Shared: Janus Henderson Investors, Frazier Life Sciences +4OMass TherapeuticsHealth · $310M in 2025–2026Shared: Sanofi, Janus Henderson InvestorsCesiumAstroDefense · $1B in 2025–2026Shared: Janus Henderson InvestorsVerdiva BioHealth · $411M in 2025–2026Shared: OrbiMed, RA Capital ManagementTubulisHealth · $401M in 2025–2026Shared: Janus Henderson Investors, Frazier Life SciencesAlphaSenseEnterprise · $350M in 2025–2026Shared: Viking Global Investors
Also in the South San Francisco hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Star Therapeutics and its logo are trademarks of their owners, used here for identification only.
